menu
    • menu
    [{"orgOrder":0,"company":"BioSyngen","sponsor":"South China Hospital of Shenzhen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BST08","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioSyngen \/ South China Hospital of Shenzhen University","highestDevelopmentStatusID":"1","companyTruncated":"BioSyngen \/ South China Hospital of Shenzhen University"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"AUM001","moa":"MNK receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"AUM Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"AUM Biosciences \/ SPRIM Global Investments","highestDevelopmentStatusID":"1","companyTruncated":"AUM Biosciences \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Xylonix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"010DS-Zn","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xylonix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xylonix \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Xylonix \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioSyngen

                            Singapore arrow
                            Vitafoods
                            Not Confirmed

                            BioSyngen

                            Singapore arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BST08

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : South China Hospital of Shenzhen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 16, 2024

                            Lead Product(s) : BST08

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : South China Hospital of Shenzhen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AUM Biosciences

                            Singapore arrow
                            Vitafoods
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM001

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : SPRIM Global Investments

                            Deal Size : $27.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            AUM Biosciences Announces Closing of $27 Million in a "Series A" Round of Funding to Advance Its Clinical Stag...

                            Details : AUM plans to use the proceeds to advance the clinical development of its portfolio with immediate initiation of two Phase II programs for MNK and TRK inhibitors including AUM001.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 13, 2021

                            Lead Product(s) : AUM001

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : SPRIM Global Investments

                            Deal Size : $27.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xylonix

                            Singapore arrow
                            Vitafoods
                            Not Confirmed

                            Xylonix

                            Singapore arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 010DS-Zn

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages

                            Details : Xylonix demonstrated that its drug compound 010DS-Zn markedly reduced M2 population, while simultaneously boosting anti-cancer CD4 and CD8 T cells.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 22, 2021

                            Lead Product(s) : 010DS-Zn

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth